Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9645713rdf:typepubmed:Citationlld:pubmed
pubmed-article:9645713lifeskim:mentionsumls-concept:C0021753lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0032005lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0035696lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0021463lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0050668lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0060623lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C2250368lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:9645713lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:9645713pubmed:issue7lld:pubmed
pubmed-article:9645713pubmed:dateCreated1998-7-17lld:pubmed
pubmed-article:9645713pubmed:abstractTextActivins and follistatins regulate all levels of the reproductive axis, including the pituitary where they stimulate and inhibit FSH production, respectively. Gonadotropes are known to express inhibin/activin betaB and activin-B (betaBbetaB) functions as an autocrine modulator of FSH production. By contrast, the mRNA for the activin-binding protein, follistatin, is present in most pituitary cells and folliculo-stellate cells may be the major source of the protein secreted by the anterior pituitary. Interleukin-1beta (IL-1beta) is one of several cytokines known to also influence the reproductive axis. IL-1beta inhibits the hypothalamo-pituitary-gonadal (HPG) axis by suppressing GnRH and gonadal steroid production. Because several pituitary cell types, including follistatin-producing folliculo-stellate cells, are targets of IL-1beta, cytokine effects on gonadotrope function were evaluated using cultured rat anterior pituitary cells. Activin-A (0.01 to 1 nM; 24h) increased basal FSH secretion approximately 2-fold. IL-1beta (0.005 to 0.5 nM) by itself had no effect on basal FSH secretion. However, IL-1beta attenuated FSH secretion in response to all concentrations of activin-A. These results suggest that the cytokine might stimulate the local production of a factor, such as follistatin, that antagonizes the action of activin-A. RNase protection analysis indicated that IL-1beta (0.005 to 5 nM) stimulated follistatin and inhibin/activin betaB mRNA accumulation in a time-dependent manner. These in vitro effects of IL-1beta were blocked by the specific IL-1 receptor antagonist (IL-lra) and were not mimicked by either rhIL-6 or lipopolysaccharide (LPS). Treatment of intact male rats with LPS (50 microg, i.v.), which increases plasma IL-1beta and induces IL-1beta expression in many tissues, including the pituitary, produced similar time-dependent increases in pituitary follistatin and inhibin/activin subunit mRNA levels. These results suggest that IL-1beta can modulate gonadotrope responses to activins by influencing the local balance of activin-B and follistatin within the pituitary.lld:pubmed
pubmed-article:9645713pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:languageenglld:pubmed
pubmed-article:9645713pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9645713pubmed:statusMEDLINElld:pubmed
pubmed-article:9645713pubmed:monthJullld:pubmed
pubmed-article:9645713pubmed:issn0013-7227lld:pubmed
pubmed-article:9645713pubmed:authorpubmed-author:ValeW WWWlld:pubmed
pubmed-article:9645713pubmed:authorpubmed-author:RivierC LCLlld:pubmed
pubmed-article:9645713pubmed:authorpubmed-author:BilezikjianL...lld:pubmed
pubmed-article:9645713pubmed:authorpubmed-author:BlountA LALlld:pubmed
pubmed-article:9645713pubmed:authorpubmed-author:CorriganA ZAZlld:pubmed
pubmed-article:9645713pubmed:authorpubmed-author:TurnbullA VAVlld:pubmed
pubmed-article:9645713pubmed:issnTypePrintlld:pubmed
pubmed-article:9645713pubmed:volume139lld:pubmed
pubmed-article:9645713pubmed:ownerNLMlld:pubmed
pubmed-article:9645713pubmed:authorsCompleteYlld:pubmed
pubmed-article:9645713pubmed:pagination3361-4lld:pubmed
pubmed-article:9645713pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:meshHeadingpubmed-meshheading:9645713-...lld:pubmed
pubmed-article:9645713pubmed:year1998lld:pubmed
pubmed-article:9645713pubmed:articleTitleInterleukin-1beta regulates pituitary follistatin and inhibin/activin betaB mRNA levels and attenuates FSH secretion in response to activin-A.lld:pubmed
pubmed-article:9645713pubmed:affiliationClayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, CA 92037, USA.lld:pubmed
pubmed-article:9645713pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9645713pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9645713pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9645713lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9645713lld:pubmed